Scientists at Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and other institutions have discovered a sign of the early development of pancreatic cancer – an upsurge in certain amino acids that occurs before the disease is diagnosed and symptoms appear. The research is being published online today by the journal Nature Medicine.
Although the increase isn't large enough to be the basis of a new test for early detection of the disease, the findings will help researchers better understand how pancreatic cancer affects the rest of the body, particularly how it can trigger the sometimes deadly muscle-wasting disease known as cachexia.
Dr. Brian Wolpin and other researchers have discovered a sign of the early development of pancreatic cancer -- an upsurge in certain amino acids that occurs before the disease is diagnosed and symptoms appear.
Credit: Dana-Farber Cancer Institute
"Most people with pancreatic ductal adenocarcinoma (PDAC) [by far the most common form of cancreatic cancer] are diagnosed after the disease has reached an advanced stage, and many die within a year of diagnosis," said Brian Wolpin, MD, MPH, of Dana-Farber, co-senior author of the new study with Matthew Vander Heiden, MD, PhD, of MIT and Dana-Farber. "Detecting the disease earlier in its development may improve our ability to treat it successfully. In this study, we asked whether PDAC produces metabolic changes – changes in the way the body uses energy and nutrients – that can be detected before the disease is diagnosed."
The researchers utilized blood samples collected years earlier from 1,500 people participating in large health-tracking studies. They analyzed the samples for more than 100 different metabolites – substances produced by the metabolic process – and compared the results from participants who had gone on to develop pancreatic cancer and those who had not.
"We found that higher levels of branched chain amino acids were present in people who went on to develop pancreatic cancer compared to those who did not develop the disease," Wolpin said. (Branched chain amino acids are one family of amino acids, the building blocks of proteins.) The amount of time that would elapse before those individuals were diagnosed with pancreatic cancer ranged from two to 25 years, although the highest risk was in the several years before diagnosis, the researchers found.
"These findings led us to hypothesize that the increase in branched chain amino acids is due to the presence of an early pancreatic tumor," Wolpin remarked. This theory was confirmed in laboratory experiments performed by Vander Heiden's group at the Koch Institute for Integrative Cancer Research at MIT. Their experiments showed that mice with newly formed pancreatic tumors had above-normal blood levels of these amino acids.
The researchers found the increase was due to a breakdown of muscle tissue, which caused branched amino acids to be released into the bloodstream. This process is similar to what occurs in patients with cancer cachexia. "What was surprising about our results was that it appears the breakdown of muscle protein begins much earlier in the disease process than previously appreciated," noted Vander Heiden.
The findings provide an important lead to scientists studying how pancreatic tumors interact with patients' normal tissues, the authors say. According to Vander Heiden, this work provides a glimpse into how pancreatic cancer changes the way the rest of the body handles nutrients. "This work has the potential to spur progress in detecting pancreatic tumors earlier and identifying new treatment strategies for those with the disease," he remarks.
The lead authors of the study are Jared Mayers, of Massachusetts Institute of Technology; Chen Wu, of Dana-Farber, Harvard School of Public Health, and the Cancer Institute and Hospital, Chinese Academy of Medical Science, Beijing, China; and Clary Clish, PhD, of the Broad Institute and Harvard University. Co-authors are Margaret Torrence, Brian Fiske, Shawn Davidson, Thales Papagiannakopoulos, PhD, and Talya Dayton of MIT; Chen Yuan, Zhi Rong Qian, MD, PhD, Douglas Rubinson, MD, PhD, Annan Yang, PhD, and Alec Kimmelman, MD, PhD, of Dana-Farber; Ying Bao, MD, ScD, and Mary Townsend, ScD, of Brigham and Women's Hospital; Shuji Ogino, MD, PhD, of Dana-Farber, Harvard School of Public Health, and Brigham and Women's Hospital; Charles Fuchs, MD, MPH, of Dana-Farber and Brigham and Women's Hospital; Peter Kraft, PhD, of Harvard School of Public Health; Shelley Tworoger, PhD, Jing Ma, MD, PhD, MPH, Meir Stampfer, MD, DrPH, Edward Giovannucci, MD, ScD, Howard Sesso, ScD, MPH, and JoAnn Manson, MD, of Harvard School of Public Health and Brigham and Women's Hospital; John Michael Gaziano, MD, MPH, of Brigham and Women's Hospital and the VA Boston Healthcare System; Barbara Cochrane, PhD, RN, of the University of Washington School of Nursing; Simin Liu, MD, MPH, ScD, of Brown University; Jean Wactawski-Wende, PhD, of the University at Buffalo, SUNY; Michael Pollak, MD, of McGill University; Amanda Souza, and Kerry Pierce of the Broad Institute of MIT and Harvard University; Thomas Wang, MD, of Vanderbilt University; and Robert Gerszten, MD, of Massachusetts General Hospital.
Major support for the study was provided by the Howard Hughes Medical Institute and the Lustgarten Foundation. Additional support came from the National Institutes of Health; the Nestle Research Center; the Robert T. and Judith B. Hale Fund for Pancreatic Cancer; the Perry S. Levy Fund for Gastrointestinal Cancer Research; the Pappas Family Research Fund for Pancreatic Cancer; Cambridge Isotope Laboratories; the Burroughs Wellcome Fund; the Damon Runyon Cancer Research Foundation; the Smith Family; the Stern Family; the American Society of Clinical Oncology Conquer Cancer Foundation; and Promises for Purple.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School, is world renowned for its leadership in adult and pediatric cancer treatment and research. Designated as a comprehensive cancer center by the National Cancer Institute (NCI), it is one of the largest recipients among independent hospitals of NCI and National Institutes of Health grant funding. For more information, go to http://www.dana-farber.org.
Anne Doerr | Eurek Alert!
Penn study identifies new malaria parasites in wild bonobos
21.11.2017 | University of Pennsylvania School of Medicine
NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures
17.11.2017 | National Institute of Standards and Technology (NIST)
The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.
Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....
The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.
Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...
Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.
That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...
Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.
During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....
The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.
Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...
15.11.2017 | Event News
15.11.2017 | Event News
30.10.2017 | Event News
21.11.2017 | Physics and Astronomy
21.11.2017 | Physics and Astronomy
21.11.2017 | Life Sciences